Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chembio Diagnostics gets CLIA Waiver for HIV test
The CLIA (Clinical Laboratory Improvement Act) waiver allows Chembio to market these rapid HIV tests to a potential market of approximately 189,000 laboratory entities across the US, including
The CLIA (Clinical Laboratory Improvement Act) waiver allows Chembio to market these rapid HIV tests to a potential market of approximately 189,000 laboratory entities across the US, including
This agreement allows Recepta Biopharma to use the PER.C6 technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Crucell’s PER.C6 technology platform
The primary endpoint of the trial was the change from baseline in the Quality of Episodic Secondary Memory (QESM) factor score of the Cognitive Drug Research (CDR) battery.
The biopharmaceutical company said it would now move forward with plans to use the final data from the Phase II trial, which are expected next year, as a
A total of 36 participants are involved in this study of which 30 received vaccine and six received placebo, this trial protocol included vaccination with two full-doses of
A total of 125 subjects were enrolled into this study. XL784 (200mg once daily for 12 weeks) was compared to placebo in subjects with macro-albuminuria who were being
The investigational compound GS 9190 is being evaluated in a two-part Phase I study of treatment-naive patients infected with HCV genotype 1. In the first part of the
The suit involves Lonza’s US sale and use of a fatty acid product currently marketed under the brand name Lonza DHA for use in functional foods and dietary
With the completion of this transaction, subsidiaries of Amerigroup acquired substantially all of the assets of Memphis Managed Care, including TLC Family Care Health Plan and MidSouth Health
Dexcel had filed its new drug application (NDA) with a paragraph IV certification stating that AstraZeneca’s patents are invalid, unenforceable, or will not be infringed under the NDA.